The National Health And Health Commission issued a number of large varieties will be focused on supervision.

On July 29, the National Health Council issued a public consultation announcement on the clinical application of anti-tumor drugs (hereinafter referred to as the Measures), and made clear requirements for the clinical use of anti-tumor drugs.
according to the announcement, the "Measures" refers to the anti-tumor drugs refers to cell killing, immune regulation, endocrine regulation and other means, at the cellular and molecular level to achieve the inhibition of tumor growth or the elimination of tumor drugs, generally including chemotherapy drugs, molecular targeted drugs, endocrine therapy drugs, immunotherapy drugs.
The Measures require the clinical application of anti-tumor drugs to be managed in a graded way.
according to safety, accessability, economy and other factors, anti-tumor drugs are divided into restricted use and general use level.
Specific classification criteria are as follows: (1) Restricting the use of grade anti-tumor drugs refers to anti-tumor drugs with one of the following characteristics: 1. Drug toxic side effects, including toxic drug management, strict adaptive evidence, taboo evidence, must be used by medical personnel with rich clinical experience, improper use of anti-tumor drugs that may cause serious harm to the human body;
(ii) General use of anti-tumor drugs refers to other anti-tumor drugs in addition to restricting the use of grade anti-tumor drugs.
addition, the Measures require medical institutions to establish a system for the selection and evaluation of anti-tumor drugs, to develop a catalogue of anti-tumor drug supplies in accordance with the needs of the diagnosis and treatment of cancer diseases in their institutions, and to adjust them regularly.
The selection of anti-tumor drug varieties in medical institutions shall be based on clinical needs, giving priority to the selection of the national basic drug catalogue, the national basic medical insurance drug catalogue, the national centralized negotiation or tender procurement, as well as the national health and health committee published diagnostic norms, clinical guidelines, clinical path recommended varieties.
, for the relevant pharmaceutical companies, in addition to the health insurance catalog, key monitoring directory, hospital procurement catalog, but also pay attention to the hospital's cancer drug supply catalog.
once anti-tumor drugs are classified as restricted, they will have an inevitable impact on their market.
billion drug market, facing the huge impact of malignant tumors is one of the most serious threats to human health and social development.
it is understood that in 184 countries and regions around the world, China's malignant tumor incidence is generally in the upper middle level, accounting for about 21.8% of the global incidence of malignant tumors.
, according to the data of Miannet, china's anti-tumor and immunomodyning drug market in 2019 reached 149.03 billion yuan, an increase of 14.55 percent year-on-year, with great market development prospects and potential.
(data source: menet) has the highest market share of anti-tumor drugs in terms of sub-categories, at 64.43 per cent, followed by immunostimides 16.64 per cent, endocrine therapy 9.84 per cent and immunosuppressants 9.09 per cent.
(data source: Minet) in the anti-tumor drugs, the current international clinical common anti-tumor drugs about 80 kinds.
, the most used protein kinase inhibitors in our clinic, the market share reached 21.22%, followed by anti-metabolic drugs 19.34 percent, monoclonal antibodies 18.93 percent.
(data source: Mi innet) is due to market demand and the huge size of the market, under strict supervision, the original market competition pattern will face inevitable impact.
In accordance with the Measures, medical institutions shall issue warnings to physicians who have had more than 3 extraordinary prescriptions and have no justifiable reasons to limit their right to prescribe;
If a physician has one of the following circumstances, the medical institution shall cancel the right to prescribe drugs: (1) it shall be ordered to suspend its practice; (2) during the period of training for failing to pass the examination; (3) it shall be cancelled or revoked its practising certificate; (4) it has not prescribed anti-tumor drugs in accordance with the provisions, resulting in serious consequences; (5) it has failed to use anti-tumor drugs in accordance with the provisions, resulting in serious consequences; and (6) it has issued prescriptions for anti-tumor drugs for improper benefits.
, for pharmaceutical companies, not only by the hospital tumor drug supply catalog, anti-tumor drug grading, but also by the doctor's prescription behavior changes.
some of the original non-compliance phenomenon, are not allowed to happen again.
with the implementation of graded management of the clinical application of national anti-tumor drugs, those drugs that are more safe, accessable and economical will usher in more market opportunities.
and those drug toxic side effects, into the toxic drug management, strict adaptation certificate, taboo certificate, expensive, heavy financial burden of drugs, will face more serious challenges.
note: There are limitations in the original text.